Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>On the latest WTR Healthcare Happenings podcast, we were joined by Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS), a late clinical stage biopharma company with a dual-oriented strategy of discovering and developing novel small molecules and repurposing already approved small molecule treatments, specifically for high burden CNS disorders, with its current primary focus on alcohol use disorder (AUD). </li><li>Solvonis is undertaking pre-clinical studies in PTSD and working to deepen its R&amp;D in addiction and psychiatry as well as broaden its interest in neurology. </li><li>Our discussion delved into the company’s lead clinical programs that aim to address this major societal problem.</li></ul>

On the latest WTR Healthcare Happenings podcast, we were joined by Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS), a late clinical stage biopharma company with a dual-oriented strategy of discovering and developing novel small molecules and repurposing already approved small molecule treatments, specifically for high burden CNS disorders, with its current primary focus on alcohol use disorder (AUD). Solvonis is undertaking pre-clinical studies in PTSD and working to deepen its R&amp;D in addiction and psychiatry as well as broaden its interest in neurology. Our discussion delved into the company’s lead clinical programs that aim to address this major societal problem.

Solvonis Demonstrates a More Effective Way to Treat High Burden Alcohol Use Disorder